Diurnal Group plc announced the appointment of three new members to its board of directors. Anders H?rfstrand joins the board as non-executive chairman, and Deborah Jorn and Jean-Michel Coss?ry join the board as non-executive directors, respectively, all with immediate effect. Following the appointment of Anders H?rfstrand as non-executive chairman, Sam Williams, who has held the role of interim chairman since March 2020, will resume his role as a non-executive director of the company and board representative of IP Group plc. Anders H?rfstrand is a leader in the pharmaceutical industry with over 30 years' experience and a sustained global track record of success in commercial operations, global marketing management and product development. Deborah Jorn is a senior commercial executive with more than 30 years of experience of successfully building US and global pharmaceutical businesses through designing and implementing innovative marketing strategies across numerous therapeutic areas, including rare diseases. Most recently, Deborah served as EVP of Corporate and Commercial Development at Eyepoint Pharmaceuticals. Prior to this, Deborah was EVP and Group Company Chair at Bausch Health (formerly Valeant Pharma) where she led the dermatology and gastroenterology businesses. Jean-Michel Coss?ry brings over 25 years of global leadership experience as a senior healthcare executive in research, marketing and commercial roles across the pharmaceutical, biotech and medtech sectors. He recently held the position of non-executive director of Kymab before it was acquired by Sanofi in April 2021 and was also Non-Executive Director of Immunocore until its successful Nasdaq IPO in January 2021. Jean-Michel is currently non-executive director at Malin and Exact Therapeutics.